The Company will hold a conference call and webcast presentation at
MANAGEMENT HIGHLIGHTS
- Net revenue for the fourth quarter of 2025 was
$252.5 million , and$946.4 million for the full year of 2025, representing decrease of (2.0)% and growth of +2.8%, respectively, when compared to the same periods of the previous year. The full year represents a new record for the corporation, driven by strong growth from our combined Cannabis business of +11.4%. - Gross profit also reached new records, with
$70.2 million in the fourth quarter of 2025, and$258.6 million for the full year, representing growth of +2.1% and +7.6%, respectively, when compared to the same periods of the previous year. - Gross margin (1) of 27.8% in the fourth quarter of 2025 and 27.3% for the full year are also new records, representing improvements of +1.1 and +1.2 percentage points, respectively, when compared to the same periods of the previous year.
- Operating Income of
$11.8 million for the fourth quarter of 2025 and$(6.3) million for the full year also represent new records, driven by gross margin progression and SG&A efficiency improvements. Excluding restructuring-related charges, Adjusted Operating Income totaled$12.8 million in the fourth quarter of 2025 and, for the first time in the Company’s history, reached break-even for the full year at$0.1 million . - Cash flow was positive by
$11.7 million in the fourth quarter of 2025 and$33.9 million for the full year, driven by contributions from operating activities. The full year also benefited from interest payments and proceeds from investments. - Free cash flow (1) was positive in the fourth quarter of 2025 at
$10.2 million and for the full year at$18.0 million , with full-year results more than doubling the prior year’s record and reflecting continued operating momentum.
“2025 represents another step forward in financial performance and strategic focus for
Beyond our financial results, during the fourth quarter of 2025 and through the first months of 2026 to date, we continued to advance several key initiatives that further strengthen our foundation for long-term success and shareholder value creation, including:
- SunStream restructuring progress: As
U.S. cannabis rescheduling gains momentum, the restructuring of the Parallel and Skymint investments continues to advance toward completion, with only a limited number of remaining requirements outstanding. - Strategic organic investments: Capital expenditures increased from
$8.6 million in 2024 to$12.8 million in 2025, including$4.0 million in the fourth quarter. The majority of these investments were directed toward new store openings across our Cannabis and Liquor Retail segments. - Acquisition of 1CM retail stores: On
January 6, 2026 ,SNDL announced the completion of the acquisition of five Cost Cannabis retail stores located inAlberta andSaskatchewan from 1CM Inc. (“1CM”). We continue to support the regulatory approval process inOntario for the remaining 27 stores. - Share buybacks: Between
December 2025 andMarch 9, 2026 , the Company repurchased 4.3 million common shares for cancellation, bringing the total numbers of shares repurchased since the fourth quarter of 2024 to 15.1 million. - Progress towards simplification & focus: With more than
$20 million in annualized savings delivered to date, the completion of the third and final phase of the corporate restructuring program, announced in mid-2024 and expected to conclude in the second quarter of 2026, positions the Company to exceed the program’s targeted savings. In addition, we are days away from completing full ERP consolidation, which will further enhance operational visibility and process efficiency.
With
TOTAL COMPANY HIGHLIGHTS
| Three months ended | Year ended | |||||||||||||||||
| ($000s) | 2025 | 2024 | % Change | 2025 | 2024 | % Change | ||||||||||||
| IFRS Financial Measures | ||||||||||||||||||
| Net revenue | 252,499 | 257,679 | -2.0 | % | 946,401 | 920,448 | 2.8 | % | ||||||||||
| Gross profit | 70,229 | 68,799 | 2.1 | % | 258,648 | 240,331 | 7.6 | % | ||||||||||
| Operating income (loss) | 11,751 | (76,089 | ) | 115.4 | % | (6,349 | ) | (103,811 | ) | 93.9 | % | |||||||
| Change in cash and cash equivalents | 11,662 | (44,617 | ) | 126.1 | % | 33,884 | 23,318 | 45.3 | % | |||||||||
| Non-IFRS Financial Measures (1) | ||||||||||||||||||
| Gross margin | 27.8 | % | 26.7 | % | 1.1 | pp | 27.3 | % | 26.1 | % | 1.2 | pp | ||||||
| Adjusted operating income (loss) | 12,801 | (60,472 | ) | 121.2 | % | 88 | (86,144 | ) | 100.1 | % | ||||||||
| Free cash flow | 10,218 | 11,625 | -12.1 | % | 17,951 | 8,872 | 102.3 | % | ||||||||||
(1) Gross Margin is a supplementary financial measure calculated by dividing Gross Profit by Net Revenue. Adjusted operating income (loss) and Free Cash Flow are specified financial measures that do not have a standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures reported by other companies. See “Non-IFRS Measures” section below for further information.
BUSINESS SEGMENT HIGHLIGHTS
| Three months ended | Year ended | |||||||||||||||||
| ($000s) | 2025 | 2024 | % Change | 2025 | 2024 | % Change | ||||||||||||
| Net Revenue | ||||||||||||||||||
| Cannabis Retail | 83,282 | 83,170 | 0.1 | % | 330,242 | 311,689 | 6.0 | % | ||||||||||
| Cannabis Operations | 37,112 | 37,092 | 0.1 | % | 144,656 | 109,470 | 32.1 | % | ||||||||||
| Intersegment Eliminations | (16,738 | ) | (16,663 | ) | -0.5 | % | (68,129 | ) | (55,970 | ) | -21.7 | % | ||||||
| Total Cannabis | 103,656 | 103,599 | 0.1 | % | 406,769 | 365,189 | 11.4 | % | ||||||||||
| Liquor Retail | 148,843 | 154,080 | -3.4 | % | 539,632 | 555,259 | -2.8 | % | ||||||||||
| Investments | — | — | 0.0 | % | — | — | 0.0 | % | ||||||||||
| Total | 252,499 | 257,679 | -2.0 | % | 946,401 | 920,448 | 2.8 | % | ||||||||||
| Operating Income | ||||||||||||||||||
| Cannabis Retail | 8,003 | (8,997 | ) | 189.0 | % | 30,332 | (1,742 | ) | 1841.2 | % | ||||||||
| Cannabis Operations | 1,874 | 4,391 | -57.3 | % | (1,754 | ) | 2,663 | -165.9 | % | |||||||||
| Total Cannabis | 9,877 | (4,606 | ) | 314.4 | % | 28,578 | 921 | 3002.9 | % | |||||||||
| Liquor Retail | 12,240 | 12,325 | -0.7 | % | 36,516 | 34,781 | 5.0 | % | ||||||||||
| Investments | 2,434 | (63,724 | ) | 103.8 | % | 4,209 | (50,013 | ) | 108.4 | % | ||||||||
| Corporate | (12,800 | ) | (20,084 | ) | 36.3 | % | (75,652 | ) | (89,500 | ) | 15.5 | % | ||||||
| Total | 11,751 | (76,089 | ) | 115.4 | % | (6,349 | ) | (103,811 | ) | 93.9 | % | |||||||
| Adjusted Operating Income | ||||||||||||||||||
| Cannabis Retail | 8,003 | 6,003 | 33.3 | % | 30,332 | 13,258 | 128.8 | % | ||||||||||
| Cannabis Operations | 2,154 | 4,439 | -51.5 | % | 2,454 | 3,091 | -20.6 | % | ||||||||||
| Total Cannabis | 10,157 | 10,442 | -2.7 | % | 32,786 | 16,349 | 100.5 | % | ||||||||||
| Liquor Retail | 12,240 | 12,325 | -0.7 | % | 36,516 | 34,781 | 5.0 | % | ||||||||||
| Investments | 2,434 | (63,724 | ) | 103.8 | % | 4,209 | (50,013 | ) | 108.4 | % | ||||||||
| Corporate | (12,030 | ) | (19,515 | ) | 38.4 | % | (73,423 | ) | (87,261 | ) | 15.9 | % | ||||||
| Total | 12,801 | (60,472 | ) | 121.2 | % | 88 | (86,144 | ) | 100.1 | % | ||||||||
Liquor Retail
| Three months ended | Year ended | |||||||||||||||||
| ($000s) | 2025 | 2024 | % Change | 2025 | 2024 | % Change | ||||||||||||
| Net revenue | 148,843 | 154,080 | -3.4 | % | 539,632 | 555,259 | -2.8 | % | ||||||||||
| Gross profit | 38,658 | 38,236 | 1.1 | % | 139,651 | 139,706 | 0.0 | % | ||||||||||
| Gross margin | 26.0 | % | 24.8 | % | 1.2 | pp | 25.9 | % | 25.2 | % | 0.7 | pp | ||||||
| Operating income | 12,240 | 12,325 | -0.7 | % | 36,516 | 34,781 | 5.0 | % | ||||||||||
| Adjusted operating income | 12,240 | 12,325 | -0.7 | % | 36,516 | 34,781 | 5.0 | % | ||||||||||
- Net revenue for Liquor Retail continued to decline in the fourth quarter of 2025, as market demand softness persisted and impacted same-store sales (2), which decreased by -4.0% in the fourth quarter and -2.3% for the full year. During the fourth quarter of 2025 two new Wine & Beyond stores were opened in
Regina (SK) andCalgary (AB) as part of the plan to expand our successful W&B format.
(2) Same-store sales is a specified financial measure that does not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. See “Non-IFRS Measures” section below for further information.
- Operating Income remained virtually flat despite revenue declines, driven by pricing and mix management strategies that supported Gross Margin improvement, including the expansion of private label offerings at accretive margins, as well as cost optimization and in-store productivity initiatives.
Cannabis Retail
| Three months ended | Year ended | |||||||||||||||||
| ($000s) | 2025 | 2024 | % Change | 2025 | 2024 | % Change | ||||||||||||
| Net revenue | 83,282 | 83,170 | 0.1 | % | 330,242 | 311,689 | 6.0 | % | ||||||||||
| Gross profit | 22,079 | 20,490 | 7.8 | % | 86,053 | 78,827 | 9.2 | % | ||||||||||
| Gross margin | 26.5 | % | 24.6 | % | 1.9 | pp | 26.1 | % | 25.3 | % | 0.8 | pp | ||||||
| Operating income | 8,003 | (8,997 | ) | 189.0 | % | 30,332 | (1,742 | ) | 1841.2 | % | ||||||||
| Adjusted operating income | 8,003 | 6,003 | 33.3 | % | 30,332 | 13,258 | 128.8 | % | ||||||||||
- Net revenue for Cannabis Retail reached a new full-year record as our Value Buds banner continued to gain market share. Same-store sales grew +3.9% for the full year, although declined by (0.7)% in the fourth quarter of 2025 driven by a market slow-down. Subsequent to year-end, the Company completed the acquisition and integration of five “Cost Cannabis” stores located in
Alberta andSaskatchewan from 1CM. - Operating Income shows strong growth in both the fourth quarter of 2025 and full year, supported by continuous gross margin expansion, including the achievement of a new full-year record, and improved SG&A cost efficiencies. The year-on-year comparison is impacted by a
$15 million Spiritleaf intangible asset impairment recorded in the fourth quarter of 2024, related to the conversion of several Spiritleaf stores to Value Buds. Adjusted Operating Income excludes this Spiritleaf intangible impairment and more clearly reflects the normalized improvement in the segment’s underlying operating profitability.
Cannabis Operations
| Three months ended | Year ended | |||||||||||||||||
| ($000s) | 2025 | 2024 | % Change | 2025 | 2024 | % Change | ||||||||||||
| Net revenue | 37,112 | 37,092 | 0.1 | % | 144,656 | 109,470 | 32.1 | % | ||||||||||
| Gross profit | 9,492 | 10,073 | -5.8 | % | 32,944 | 21,798 | 51.1 | % | ||||||||||
| Gross margin | 25.6 | % | 27.2 | % | -1.6 | pp | 22.8 | % | 19.9 | % | 2.9 | pp | ||||||
| Operating income (loss) | 1,874 | 4,391 | -57.3 | % | (1,754 | ) | 2,663 | -165.9 | % | |||||||||
| Adjusted operating income (loss) | 2,154 | 4,439 | -51.5 | % | 2,454 | 3,091 | -20.6 | % | ||||||||||
- Cannabis Operations reported a new full-year Net Revenue record. This expansion is mainly driven by edibles, following Indiva’s acquisition in the fourth quarter of 2024, as well as international sales growing from
$3.6 million in 2024 to$12.6 million in 2025. - While the segment achieved a new full-year Gross Margin record, results were impacted in the third quarter of 2025 by inventory write-offs and valuation adjustments related to the cultivation ramp-up, and the fixed-asset write-off of the idle
Stellarton facility, as well as by restructuring charges related to the Indiva integration mostly during the first quarter of 2025.
Investments
- As of
December 31, 2025 , the Company has deployed capital to a portfolio of cannabis-related investments with a carrying value of$397.6 million , including$385.5 million toSunStream Bancorp Inc. (“SunStream”). This carrying value was reduced by$5.6 million during the fourth quarter of 2025, primarily due to a decrease in the USD to CAD exchange rate from 1.3921 onSeptember 30, 2025 to 1.3706 onDecember 31, 2025 . - The previously disclosed restructuring process relating to Skymint continues.
SNDL is awaiting an update from theMichigan Supreme Court expected in Q3 2026, which is expected to determine whether the court will accept the case for further review. Timing and outcomes remain uncertain and subject to court process and other factors. - The previously disclosed restructuring process relating to Parallel continues. On
February 4, 2025 , theFlorida Department of Health approved the transfer of Parallel’s license, representing an important milestone in completing Parallel’s restructuring process. InDecember 2025 , a settlement was reached resolving the final remaining litigation, andSNDL currently expects the strict foreclosure process to close in Q3 2026, subject to completion of remaining steps, satisfaction of applicable conditions, and any required approvals. - SunStream continues to hold exposure to
The Cannabist Company Holdings Inc. (“Cannabist”) through the senior secured notes, with an aggregate position of approximately$35 million and estimated NAV of$28.3 million . Forecasted liquidity challenges have led Cannabist to pursue asset divestitures. Based on scenarios reviewed by Cannabist’s advisors,SNDL believes there is a pathway to full recovery of the senior secured notes relative to current NAV estimates, although outcomes remain subject to execution risk and other uncertainties. - The investment portfolio generated a positive operating income of
$2.4 million in the fourth quarter of 2025 and$4.2 million in the full year, primarily driven by interests earned from our cash accounts. - On
December 18, 2025 ,U.S. PresidentDonald Trump issued an executive order directing theDepartment of Justice to expedite the process to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act. The order did not itself reclassify cannabis but instead directed regulators to finalize an ongoing rulemaking process. If finalized, while not constituting federal legalization, reclassification is expected to improve tax exposure for companies operating in theU.S. through the elimination of Section 280E, expand medical research and regulatory clarity, and incrementally enhance access to capital. These developments would meaningfully improve industry economics and investability.
Equity Position
$649.9 million of unrestricted cash, marketable securities and investments, including investments in equity-accounted investees, and no outstanding debt atDecember 31, 2025 , resulting in a net book value of$1.1 billion .
- The board of directors of the Company has approved the renewal of its Share Repurchase Program upon the expiry of its share repurchase program on
November 20, 2025 .
- For the three months ended
December 31, 2025 , the Company purchased for cancellation 136,362 common shares at a weighted average price, excluding commissions, ofUS$1.64 per share. Subsequent to year-end, betweenJanuary 1, 2026 andMarch 9, 2026 the Company purchased and cancelled an additional 4,153,358 common shares at a weighted average price, excluding commissions, ofUS$1.56 per share.SNDL will continue to evaluate opportunities to utilize the program to the extent that management believes it is in the best interest of SNDL’s shareholders. As a reminder, since the fourth quarter of 2024 the Company has repurchased 15,055,627 common shares for cancellation.
This press release is intended to be read in conjunction with the Company’s consolidated financial statements and the notes thereto for the years ended
CONFERENCE CALL?
The Company will hold a conference call and webcast presentation at
WEBCAST ACCESS
To access the live webcast of the call, please visit the following link:
https://edge.media-server.com/mmc/p/aps8jm4e
REPLAY
A replay of the webcast will be available at https://sndl.com/financials/quarterly-results/default.aspx
ABOUT SNDL INC.
For more information:
SNDL Inc.
O: 1.587.327.2017
E: investors@sndl.com
Forward-Looking Information Cautionary Statement???
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company’s operational goals, plans and key priorities, the Company’s ability to deploy capital and the expected benefits thereof, the growth opportunities available to
| Condensed Consolidated Statement of Loss and Comprehensive Loss (Expressed in thousands of Canadian dollars, except per share amounts) | ||||||||
| Year ended | ||||||||
| 2025 | 2024 | |||||||
| Net revenue | 946,401 | 920,448 | ||||||
| Cost of sales | 687,753 | 680,117 | ||||||
| Gross profit | 258,648 | 240,331 | ||||||
| Investment income | 7,814 | 15,551 | ||||||
| Share of loss of equity-accounted investees | (3,605 | ) | (65,459 | ) | ||||
| General and administrative | 182,162 | 187,243 | ||||||
| Sales and marketing | 14,565 | 12,004 | ||||||
| Depreciation and amortization | 51,948 | 54,250 | ||||||
| Share-based compensation | 13,905 | 20,037 | ||||||
| Restructuring costs | 3,337 | 2,667 | ||||||
| Asset impairment, net | 2,618 | 17,317 | ||||||
| Research and development | 489 | 346 | ||||||
| Loss on disposition of assets | 182 | 370 | ||||||
| Operating loss | (6,349 | ) | (103,811 | ) | ||||
| Other expenses, net | (9,425 | ) | (1,798 | ) | ||||
| Loss before income tax | (15,774 | ) | (105,609 | ) | ||||
| Income tax recovery | — | 9,405 | ||||||
| Net loss | (15,774 | ) | (96,204 | ) | ||||
| Equity-accounted investees - share of other comprehensive (loss) income | (19,233 | ) | 31,489 | |||||
| Investments at fair value through other comprehensive income ("FVOCI") - change in fair value | 5,358 | 1,864 | ||||||
| Comprehensive loss | (29,649 | ) | (62,851 | ) | ||||
| Net loss attributable to: | ||||||||
| Owners of the Company | (15,774 | ) | (94,796 | ) | ||||
| Non-controlling interest | — | (1,408 | ) | |||||
| (15,774 | ) | (96,204 | ) | |||||
| Comprehensive loss attributable to: | ||||||||
| Owners of the Company | (29,649 | ) | (61,443 | ) | ||||
| Non-controlling interest | — | (1,408 | ) | |||||
| (29,649 | ) | (62,851 | ) | |||||
| Net loss per common share attributable to owners of the Company | ||||||||
| Basic and diluted | $ | (0.06 | ) | $ | (0.36 | ) | ||
| Condensed Consolidated Statement of Financial Position (Expressed in thousands of Canadian dollars) | ||||||
| As at | ||||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | 252,243 | 218,359 | ||||
| Restricted cash | 20,081 | 19,815 | ||||
| Marketable securities | 84 | 139 | ||||
| Accounts receivable | 27,643 | 28,118 | ||||
| Biological assets | 3,120 | 1,187 | ||||
| Inventory | 126,877 | 127,919 | ||||
| Prepaid expenses and deposits | 15,566 | 16,860 | ||||
| Investments | 484 | 27,560 | ||||
| Assets held for sale | 746 | 19,051 | ||||
| Net investment in subleases | 2,775 | 2,832 | ||||
| 449,619 | 461,840 | |||||
| Non-current assets | ||||||
| Long-term deposits and receivables | 4,526 | 3,679 | ||||
| Right of use assets | 138,353 | 115,435 | ||||
| Property, plant and equipment | 151,900 | 145,810 | ||||
| Net investment in subleases | 11,643 | 15,354 | ||||
| Intangible assets | 58,520 | 61,325 | ||||
| Investments | 11,574 | 8,427 | ||||
| Equity-accounted investees | 385,534 | 413,124 | ||||
| 124,248 | 124,248 | |||||
| Total assets | 1,335,917 | 1,349,242 | ||||
| Liabilities | ||||||
| Current liabilities | ||||||
| Accounts payable and accrued liabilities | 56,747 | 56,275 | ||||
| Lease liabilities | 35,462 | 34,256 | ||||
| Derivative warrants | — | 26 | ||||
| 92,209 | 90,557 | |||||
| Non-current liabilities | ||||||
| Lease liabilities | 134,471 | 118,017 | ||||
| Other liabilities | 8,041 | 7,312 | ||||
| Total liabilities | 234,721 | 215,886 | ||||
| Shareholders’ equity | ||||||
| Share capital | 2,310,398 | 2,346,728 | ||||
| Warrants | 306 | 667 | ||||
| Contributed surplus | 54,038 | 57,156 | ||||
| Accumulated deficit | (1,302,441 | ) | (1,323,965 | ) | ||
| Accumulated other comprehensive income ("AOCI") | 38,895 | 52,770 | ||||
| Total shareholders’ equity | 1,101,196 | 1,133,356 | ||||
| Total liabilities and shareholders’ equity | 1,335,917 | 1,349,242 | ||||
| Condensed Consolidated Statement of Cash Flows (Expressed in thousands of Canadian dollars) | ||||||||
| Year ended | ||||||||
| 2025 | 2024 | |||||||
| Cash provided by (used in): | ||||||||
| Operating activities | ||||||||
| Net loss for the period | (15,774 | ) | (96,204 | ) | ||||
| Adjustments for: | ||||||||
| Income tax recovery | — | (9,405 | ) | |||||
| Interest and fee income | (7,436 | ) | (15,637 | ) | ||||
| Change in fair value of biological assets | (2,322 | ) | 675 | |||||
| Change in fair value of inventory sold | 1,252 | (1,567 | ) | |||||
| Share-based compensation | 13,905 | 20,037 | ||||||
| Depreciation and amortization | 56,271 | 56,711 | ||||||
| Loss on disposition of assets | 182 | 370 | ||||||
| Inventory impairment and obsolescence | 2,671 | 3,707 | ||||||
| Finance costs, net | 6,693 | 7,161 | ||||||
| Change in estimate of fair value of derivative warrants | (26 | ) | (4,374 | ) | ||||
| Unrealized foreign exchange loss | 614 | 108 | ||||||
| Transaction costs | — | 164 | ||||||
| Bargain purchase gain | — | (5,456 | ) | |||||
| Asset impairment, net | 2,618 | 17,317 | ||||||
| Share of loss of equity-accounted investees | 3,605 | 65,459 | ||||||
| Unrealized (gain) loss on marketable securities | (378 | ) | 86 | |||||
| Additions to marketable securities | 433 | — | ||||||
| Income distributions from equity-accounted investees | 68 | 10,715 | ||||||
| Interest received | 7,109 | 12,494 | ||||||
| Change in non-cash working capital | 1,432 | (7,447 | ) | |||||
| Net cash provided by operating activities | 70,917 | 54,914 | ||||||
| Investing activities | ||||||||
| Additions to property, plant and equipment | (12,811 | ) | (8,615 | ) | ||||
| Additions to intangible assets | — | (2,404 | ) | |||||
| Additions to investments | (16,414 | ) | (36,155 | ) | ||||
| Principal payments from investments | 27,488 | 13,538 | ||||||
| Proceeds from disposal of investments | 18,090 | — | ||||||
| Capital refunds from equity-accounted investees | — | 168 | ||||||
| Capital distributions from equity-accounted investees | 4,684 | 89,758 | ||||||
| Proceeds from disposal of property, plant and equipment | 813 | 734 | ||||||
| Acquisitions, net of cash acquired | (3,000 | ) | (39,644 | ) | ||||
| Change in non-cash working capital | (1,396 | ) | 383 | |||||
| Net cash provided by investing activities | 17,454 | 17,763 | ||||||
| Financing activities | ||||||||
| Change in restricted cash | (267 | ) | 76 | |||||
| Payments on lease liabilities, net | (39,245 | ) | (36,952 | ) | ||||
| Repurchase of common shares | (15,348 | ) | (13,219 | ) | ||||
| Proceeds from issuance of shares, net of costs | — | (59 | ) | |||||
| Issuance of common shares by subsidiaries | — | 174 | ||||||
| Change in non-cash working capital | 373 | 621 | ||||||
| Net cash used in financing activities | (54,487 | ) | (49,359 | ) | ||||
| Change in cash and cash equivalents | 33,884 | 23,318 | ||||||
| Cash and cash equivalents, beginning of period | 218,359 | 195,041 | ||||||
| Cash and cash equivalents, end of period | 252,243 | 218,359 | ||||||
NON-IFRS MEASURES
Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS.?These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company’s operating results in the same manner as the management team.?
ADJUSTED OPERATING INCOME (LOSS)
Adjusted operating income (loss) is a non-IFRS financial measure which the Company uses to evaluate its operating performance in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.
The following tables reconcile adjusted to un-adjusted operating income (loss) for the periods noted.
| ($000s) | Cannabis Retail | Cannabis Operations | Cannabis Total | Liquor Retail | Investments | Corporate | Total | ||||||||||||||
| Three months ended | |||||||||||||||||||||
| Operating income (loss) | 8,003 | 1,874 | 9,877 | 12,240 | 2,434 | (12,800 | ) | 11,751 | |||||||||||||
| Adjustments: | |||||||||||||||||||||
| Restructuring costs | — | 280 | 280 | — | — | 770 | 1,050 | ||||||||||||||
| Impairments triggered by restructuring | — | — | — | — | — | — | — | ||||||||||||||
| Adjusted operating income (loss) | 8,003 | 2,154 | 10,157 | 12,240 | 2,434 | (12,030 | ) | 12,801 | |||||||||||||
| ($000s) | Cannabis Retail | Cannabis Operations | Cannabis Total | Liquor Retail | Investments | Corporate | Total | ||||||||||||||
| Year ended | |||||||||||||||||||||
| Operating income (loss) | 30,332 | (1,754 | ) | 28,578 | 36,516 | 4,209 | (75,652 | ) | (6,349 | ) | |||||||||||
| Adjustments: | |||||||||||||||||||||
| Restructuring costs | — | 1,108 | 1,108 | — | — | 2,229 | 3,337 | ||||||||||||||
| Impairments triggered by restructuring | — | 3,100 | 3,100 | — | — | — | 3,100 | ||||||||||||||
| Adjusted operating income (loss) | 30,332 | 2,454 | 32,786 | 36,516 | 4,209 | (73,423 | ) | 88 | |||||||||||||
| ($000s) | Cannabis Retail | Cannabis Operations | Cannabis Total | Liquor Retail | Investments | Corporate | Total | ||||||||||||||
| Three months ended | |||||||||||||||||||||
| Operating income (loss) | (8,997 | ) | 4,391 | (4,606 | ) | 12,325 | (63,724 | ) | (20,084 | ) | (76,089 | ) | |||||||||
| Adjustments: | |||||||||||||||||||||
| Restructuring costs (recovery) | — | 48 | 48 | — | — | 569 | 617 | ||||||||||||||
| 15,000 | — | 15,000 | — | — | — | 15,000 | |||||||||||||||
| Adjusted operating income (loss) | 6,003 | 4,439 | 10,442 | 12,325 | (63,724 | ) | (19,515 | ) | (60,472 | ) | |||||||||||
| ($000s) | Cannabis Retail | Cannabis Operations | Cannabis Total | Liquor Retail | Investments | Corporate | Total | ||||||||||||||
| Year ended | |||||||||||||||||||||
| Operating income (loss) | (1,742 | ) | 2,663 | 921 | 34,781 | (50,013 | ) | (89,500 | ) | (103,811 | ) | ||||||||||
| Adjustments: | |||||||||||||||||||||
| Restructuring costs | — | 428 | 428 | — | — | 2,239 | 2,667 | ||||||||||||||
| 15,000 | — | 15,000 | — | — | — | 15,000 | |||||||||||||||
| Adjusted operating income (loss) | 13,258 | 3,091 | 16,349 | 34,781 | (50,013 | ) | (87,261 | ) | (86,144 | ) | |||||||||||
GROSS MARGIN
Gross margin is a supplementary financial measure calculated as gross profit divided by net revenue for the periods presented. This measure evaluates the underlying profitability of our operations and provides useful information about the Company’s ability to price products effectively, manage input costs, drive operating efficiencies, and compare results across periods and business segments
FREE CASH FLOW
Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance, providing information which management believes to be useful in understanding and evaluating the Company’s ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).
The following table reconciles free cash flow to change in cash and cash equivalents for the periods noted.
| Three months ended | Year ended | |||||||||||||||
| ($000s) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Change in cash and cash equivalents | 11,662 | (44,617 | ) | 33,884 | 23,318 | |||||||||||
| Adjustments: | ||||||||||||||||
| Repurchase of common shares | 314 | 13,219 | 15,348 | 13,219 | ||||||||||||
| Changes to long-term investments | (3,758 | ) | 5,033 | (34,281 | ) | (67,309 | ) | |||||||||
| Acquisitions, net of cash acquired | 2,000 | 37,990 | 3,000 | 39,644 | ||||||||||||
| Free cash flow | 10,218 | 11,625 | 17,951 | 8,872 | ||||||||||||
SAME STORE SALES
Same store sales is a non-IFRS financial measure which the Company uses to evaluate its financial performance in its retail segments. Same store sales provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company’s sales trends excluding the effect of the opening and closure of stores.
Same store sales refers to the revenue generated by the Company’s existing retail locations during the current and prior comparison periods.
ADJUSTED EBITDA
Adjusted EBITDA is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company’s operating results. The Company defines adjusted EBITDA as net earnings (loss) before inventory and biological assets fair value and impairment adjustments, share of (gain) loss of equity-accounted investees, depreciation and amortization, share-based compensation expense, restructuring costs, asset impairment, gain or loss on disposal of property, other expenses, net, income tax expense (recovery) and excluding non-recurring items including enterprise resource planning (“ERP”) implementation costs and litigation settlements, net of recoveries.
| Three months ended | Year ended | |||||||||||||||
| ($000s) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net earnings (loss) | 9,367 | (67,249 | ) | (15,774 | ) | (96,204 | ) | |||||||||
| Adjustments: | ||||||||||||||||
| Inventory and biological assets fair value and impairment adjustments | 184 | (179 | ) | 1,601 | 2,615 | |||||||||||
| Share of (gain) loss of equity-accounted investees | (782 | ) | 66,458 | 3,605 | 65,459 | |||||||||||
| Depreciation and amortization | 12,872 | 13,199 | 51,948 | 54,250 | ||||||||||||
| Share-based compensation | (1,285 | ) | 4,609 | 13,905 | 20,037 | |||||||||||
| Restructuring costs | 1,050 | 617 | 3,337 | 2,667 | ||||||||||||
| Asset impairment | (353 | ) | 15,000 | 2,618 | 17,317 | |||||||||||
| Loss (gain) on disposition of PP&E | 236 | (71 | ) | 182 | 370 | |||||||||||
| Other expenses, net | 2,384 | (2,282 | ) | 9,425 | 1,798 | |||||||||||
| Income tax recovery | — | (6,558 | ) | — | (9,405 | ) | ||||||||||
| Non-recurring items | 75 | 181 | (621 | ) | 882 | |||||||||||
| Adjusted EBITDA | 23,748 | 23,725 | 70,226 | 59,786 | ||||||||||||
Source: 